



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

25th June 2015 - News release

INHALED L-DOPA CLINICAL TRIAL RESULTS

CVT-301 is the name of an inhaled version of L-dopa presently being developed for the treatment of Parkinson's Disease. Clinical trial results demonstrated improved efficacy that was apparent in only 10 minutes. CVT-301 uses the ARCUS inhalation technology, which delivers a reliable and consistent drug dose with a compact, breath actuated inhaler. The inhaled version of L-dopa would be used alongside the use of oral L-dopa.



The clinical trial showed that patients experiencing an OFF episode, treated with either 35mg or 50mg CVT-301, had significantly greater improvements in motor function than patients treated with inhaled placebo. The difference in improvement was already apparent 10 minutes after dosing and was durable for at least an hour, the longest time point at which patients were measured. This enables fast working L-dopa unlike what has ever been seen before.

Both doses of CVT-301 were well tolerated, with no increase relative to placebo in troublesome or non-troublesome dyskinesias during ON periods. The most common adverse events were dizziness, headache and cough; there were no adverse events on cardiovascular or lung function. For more information go to :

<http://ir.acorda.com/investors/investor-news/investor-news-details/2015/Acorda-Presents-Data-on-Inhaled-Levodopa-Therapy-CVT-301-at-International-Congress-of-Parkinsons-Disease-and-Movement-Disorders/default.aspx>

Based on the results of the Phase 2b clinical trial, Acorda has initiated a Phase 3 clinical trial in order to assess efficacy that is expected to enroll approximately 345 participants who will take either 50mg, 35mg, or placebo, just as were used in the Phase 2b clinical trial.

<http://www.viartis.net/parkinsons.disease/news/150625.pdf>

mail@viartis.net

©2015 Viartis